Literature DB >> 1173234

Effect of ergot drugs on central 5-hydroxytryptamine neurons: evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation.

H Corrodi, L O Farnebo, K Fuxe, B Hamberger.   

Abstract

In combined biochemical and functional studies it has been possible to show that ergocornine (0.5-5 mg/kg) and the ergolene derivative (5R,8R)-8-(4-p-methoxyphenyl-1-piperazinylmethyl)-6-methylergolene (PTR 17402; MPME) (0.25-5 mg/kg) reduce in a dose-dependent way brain 5-hydroxytryptamine (5-HT) turnover in rat as evaluated with the tryptophan hydroxylase inhibitor, alpha-propyl-dopacetamide (H 22/54), whereas 2-Br-alpha-ergocryptine (CB 154; Br-EC) had no effect on brain 5-HT turnover. Effects on 5-HT receptor activity were evaluated using the extensor hindlimb reflex of acutely spinalized rats. It was found that ergocornine increased the 5-HT receptor activity independent of presynaptic 5-HT stores and that it didnot have any effects on uptake, retention and spontaneous overflow of 3-H-5-HT in vitro but reduced the fiedl stimulation-induced release of 3-H-5-HT in vitro. Therefore, it is suggested that ergocornine is a 5-HT recpetor-stimulating agent, an effect which may lead to reduction of nervous impulse flow in the 5-HT neurons and subsequently of 5-HT release and turnover. MPME, on the other hand, seems to increase 5-HT receptor release of 5-HT stores, mainly from extragranular sites. Thus, the increase in extensor reflex activity found after MPME was reduced by reserpine and H 22/54 and enhanced by nialamide and in vitro MPME markedly increased 3-H-5-HT overflow in cortical slices of nialamide-pretreated rats and inhibited uptake and retention of 3-H-5-HT (EC50 equals 1.6 times 10-minus 6 M) in cortical slices of normal rats. Inhibition of the 5-HT membrane pump does not seem to be of any major importance, since chlorimipramine was only weakly active on the extensor reflex in the pharmacological models used and since MPME did not block but rather enhanced the 5-HT depletion caused by 4-methyl-alpha-ethyl-m-tyramine. It is suggested that MPME is a releaser of extragranular 5-HT stores leading to increased 5-HT receptor activity and reduction of 5-HT turnover in the same way as indicated for ergocornine. This new ergolene derivative may represent a new class of antidepressant drugs acting via release of extragranular 5-HT stores.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1173234     DOI: 10.1016/0014-2999(75)90097-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Bromocriptine and dopamine receptor stimulation.

Authors:  A G Debono; C D Marsden; P Asselman; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

2.  Effects of morphine, physostigmine and raphe nuclei stimulation on 5-hydroxytryptamine release from the cerebral cortex of the cat.

Authors:  P Aiello-Malmberg; A Bartolini; R Bartolini; A Galli
Journal:  Br J Pharmacol       Date:  1979-04       Impact factor: 8.739

Review 3.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.

Authors:  J D Parkes; A G Debono; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-11       Impact factor: 10.154

5.  Inhibition of reserpine-induced PGO waves in the cat by ergot derivatives.

Authors:  P E Züger; J M Vigouret; D M Loew
Journal:  Experientia       Date:  1978-05-15

6.  Blockade of photically induced epilepsy by 'dopamine agonist' ergot alkaloids.

Authors:  G Anlezark; B Meldrum
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

Review 7.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

8.  EEG sleep patterns in Parkinsonian patients treated with bromocryptine and L-dopa: a comparative study.

Authors:  J Vardi; H Glaubman; J Rabey; M Streifler
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

9.  Is receptor activation involved in the mechanism by which (+)-fenfluramine and (+)-norfenfluramine deplete 5-hydroxytryptamine in the rat brain?

Authors:  R Invernizzi; K Kmieciak-Kolada; R Samanin
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

10.  Long-term treatment of Parkinson's disease with bromocriptine.

Authors:  A Rascol; B Guiraud; J L Montastruc; J David; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.